The present invention relates to a novel method for the diagnosis of Alzheimer's disease using cerebrospinal fluid. More particularly, this method consists in contacting a sample of cerebrospinal fluid which contains a glutamine synthetase, having an apparent MT of about 42 000 daltons, with a labeled antibody specific for said glutamine synthetase under conditions that allow the formation of glutamine synthetase-antibody complex formation ; detecting the presence of said glutamine synthetase-antibody complexes ; and correlating the presence of said complexes with the presence of Alzheimer's disease.
Detection of Alzheimer's disease from cerebrospinal fluid using an immunoassay method